StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Choice Broking

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byChoice BrokingHorizon: NA (inferred 1–3 months)20 Aug 2026via Economic Times Stock Recos Overview

Entry₹2,331Inferred
Target₹2,590
Total upside +11.11%
Stop lossNot given
CMP₹2,198.5Just now
Active-5.68%+17.81%upside left 4 wk left
Follow Choice Broking for new callsGet alertsWatch GLENMARK for new buy/sell callsGet alertsSee 1 other Short-term call on GLENMARKSee 43 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 5:03 pm IST
33 supporting9 neutral4 opposing
Supports the BUY call (33)

RSI at 25 — oversold territory

Technicals · rsi·22 Oct · today

Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) in India with Weekly Treatment Starting at ₹325

NewsGoogle News·19 Oct · 3d ago

(opens in new tab)

5 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·19 Oct · 3d ago

Glenmark Pharma's biotech arm IGI unveils ISB 2301 to target solid tumors

NewsGoogle News·17 Oct · 5d ago

(opens in new tab)

Glenmark stock gained 0.70 percent after US acne launch

NewsGoogle News·7 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (9)

Glenmark Pharmaceuticals (NSE: GLENMARK) U.S. FDA Compliance Update for Goa Facility

NewsGoogle News·23 Sept · 4w ago

(opens in new tab)

Glenmark transfers nebulizer brands to subsidiary for ₹223 Cr

NewsGoogle News·23 Sept · 4w ago

(opens in new tab)
Weighs against the BUY call (4)

MACD below its signal line — bearish momentum

Technicals · macd·22 Oct · today

Glenmark USA settles antitrust suits for $29.628 million

NewsGoogle News·18 Oct · 4d ago

(opens in new tab)

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·3 Feb · 9mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Choice Broking

Every call and its outcome